ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Rating) shares traded up 1% during trading on Friday . The stock traded as high as $12.77 and last traded at $12.77. 45 shares were traded during mid-day trading, a decline of 100% from the average session volume of 179,238 shares. The stock had previously closed at $12.64.
Analysts Set New Price Targets
Several analysts have recently commented on the company. Stifel Nicolaus reduced their price target on ALX Oncology from $35.00 to $16.00 in a report on Monday, June 6th. Credit Suisse Group reduced their price target on ALX Oncology from $43.00 to $38.00 and set an “outperform” rating for the company in a report on Tuesday, August 9th. Finally, Cantor Fitzgerald reduced their price objective on ALX Oncology from $60.00 to $32.00 in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.83.
ALX Oncology Stock Down 3.6 %
The firm has a fifty day moving average of $12.24 and a 200-day moving average of $12.37. The stock has a market capitalization of $496.34 million, a price-to-earnings ratio of -4.48 and a beta of 1.84.
Hedge Funds Weigh In On ALX Oncology
About ALX Oncology
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.
- Get a free copy of the StockNews.com research report on ALX Oncology (ALXO)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.